AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17324243
Drug: Desloratadine syrup
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine syrup 1.25 mg (2.5 ml) for children aged > or =1 year to < or =2 years
Trial: 17324243
Drug: Desloratadine syrup
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine syrup 5 mg for adults
Trial: 17324243
Drug: Doses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of 1.0 mg for children aged > or =6 months to <1 year and 1.25 mg for children aged > or =1 year to < or =2 years
Trial: 14655041
Drug: ramosetron 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramosetron 300 microg plus dexamethasone 20 mg
Trial: 14655041
Drug: ramosetron 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramosetron 100 microg once daily plus dexamethasone 8 mg twice daily
Trial: 14655041
Drug: ramosetron 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramosetron 100 microg once daily
Trial: 9700710
Drug: Monthly fast
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly fast fluid attenuated inversion recovery (FLAIR) scans associated with enhanced MRI after the injection of a triple dose (TD) of gadolinium (Gd)
Trial: 9700710
Drug: Monthly dual‐echo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly dual‐echo spin‐echo (SE) and enhanced magnetic resonance imaging (MRI) after the injection of a standard dose (SD) of gadolinium (Gd)
Trial: 7924370
Drug: 1% l-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% l-epinephrine
Trial: 2572260
Drug: Atenolol (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (a selective beta 1‐adrenoceptor antagonist)
Trial: 2572260
Drug: Xamoterol (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (a beta 1‐adrenoceptor partial agonist with 43% agonist activity)
Trial: 23601909
Drug: Physiological buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological buffered saline solution (Group 4)
Trial: 21843921
Drug: Neoadjuvant trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant trastuzumab plus chemotherapy
Trial: 15001604
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein supplement (0.75 g/kg)
Trial: 15001604
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein supplement (0.04 g/kg)
Trial: 15273093
Drug: Topical nitrogen
RxNorm normalized name: nitrogen Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitrogen oxides (sodium nitrite 6%, citric acid monohydrate 9%) applied daily for 6 weeks
Trial: 15273093
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied daily for 6 weeks
Trial: 15273093
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received nitrogen oxide-generating creams for the second 6 weeks
Trial: 10994918
Drug: Carbohydrate drink
RxNorm normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate drink (16 mL x kg(‐1) of a drink containing 7.6 g x 100 mL(‐1) carbohydrate)
Trial: 1287378
Drug: Heparin lock
RxNorm normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin lock (HPL)
Trial: 3546153
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg (single oral dose)
Trial: 3546153
Drug: Ofloxacin 300
RxNorm normalized name: ofloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 300 mg b.i.d. (seven-day course)
Trial: 3546153
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg b.i.d. (seven-day course)
Trial: 2899536
Drug: sulphasalazine 2
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sulphasalazine 2 g daily
Trial: 2899536
Drug: mesalazine 800
RxNorm normalized name: mesalazine 800 MG Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine 800 mg daily
Trial: 2899536
Drug: mesalazine 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine 2.4 g daily
Trial: 26517214
Drug: bromazepam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromazepam (6 mg)
Trial: 26517214
Drug: modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modafinil (200 mg)
Trial: 21996071
Drug: Tape-OCA combination
RxNorm normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tape-OCA combination
Trial: 17399972
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 microg inhalation
Trial: 16132321
Drug: celecoxib, 200
RxNorm normalized name: Celecoxib, 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib, 200 mg by mouth
Trial: 16132321
Drug: rofecoxib, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rofecoxib, 50 mg by mouth
Trial: 16132321
Drug: diclophenac sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclophenac sodium, 75 mg intramuscularly
Trial: 16132321
Drug: placebo, pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, pill
Trial: 3128114
Drug: Cefoxitin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (multiple 2 gm doses)
Trial: 23090004
Drug: Risperidone +
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone + Ulinastatin (Risperidone 1 mg orally 30-60 min before ERCP, Ulinastatin 150000 U intravenously for 10 min prior to ERCP)
Trial: 21084763
Drug: Linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (5 mg/day × 6 days)
Trial: 21084763
Drug: Glyburide (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (1.75 mg/day × 1 day)
Trial: 16415641
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy with fibrinolytic agents
Trial: 15383186
Drug: Oral propionyl-L-carnitine
RxNorm normalized name: glycine propionyl-L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propionyl-L-carnitine (PLC) 2 g/day plus sildenafil 50 mg twice weekly (Group 1)
Trial: 9558831
Drug: Control (vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (vaccine only, no OMT)
Trial: 21341146
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block with 0.5% levobupivacaine (30 mL) followed by interscalene infusion: 0.125% levobupivacaine 5 mL/h basal infusion, 5 mL bolus dose, 20 min lockout time.
Trial: 21341146
Drug: Subacromial infusion:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial infusion: 0.125% levobupivacaine 5 mL/h basal infusion, 5 mL bolus dose, 20 min lockout time.
Trial: 19639303
Drug: Broad Spectrum
RxNorm normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Broad Spectrum Treatment (BST) with extended Naltrexone (NTX)
Trial: 19639303
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) with extended Naltrexone (NTX)
Trial: 19639303
Drug: Broad Spectrum
RxNorm normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Broad Spectrum Treatment (BST) with short Naltrexone (NTX)
Trial: 19639303
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) with short Naltrexone (NTX)
Trial: 6652642
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after initial treatment
Trial: 11783837
Drug: Amitryptiline, ondansetron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitryptiline, ondansetron, zoldipem, growth hormone
Trial: 11783837
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs, malic acid with magnesium, calcitonin injections, s-adenyl-L-methionine
Trial: 9131679
Drug: 20% long‐chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% long‐chain triacylglycerols (LCT) with 55% of linoleic acid and 7% of alpha linolenic acid in 100 g of emulsion
Trial: 9131679
Drug: 20% medium‐chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% medium‐chain triacyglycerols (MCT) and LCT with 26% of linoleic acid and 4% of alpha linolenic acid in 100 g of emulsion
Trial: 8198026
Drug: Low-density lipoprotein
RxNorm normalized name: Low-density lipoprotein receptor kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-density lipoprotein (LDL) apheresis with a dextran sulfate cellulose column; pravastatin 10 mg and niacin 1,500 mg daily for some patients.
Trial: 3283916
Drug: Maintenance ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance ranitidine therapy (150 mg at night)
Trial: 20372175
Drug: Low EGCG
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low EGCG (300 mg)
Trial: 20372175
Drug: High EGCG
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High EGCG (600 mg)
Trial: 20372175
Drug: EGCG/Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG/Caffeine (300 mg/200 mg)
Trial: 10473894
Drug: Doxapram (0.5‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (0.5‐2 mg/kg/h intravenously or 2‐8 mg/kg every 2 h orally)
Trial: 9772585
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Western and traditional Chinese medicine (Astragalus membranaceus, taurine, coenzyme Q10, antiarrhythmics)
Trial: 9772585
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (glucose‐insulin‐potassium (GIK), coenzyme Q10, antiarrhythmics)
Trial: 24979303
Drug: LDL-C target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C target A (2.8-1.8 mmol/l)
Trial: 24979303
Drug: LDL-C target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C target B (<1.8 mmol/l)
Trial: 19675505
Drug: Tapering down
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering down of combined estrogen plus progestogen therapy (EPT)
Trial: 19675505
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation of combined estrogen plus progestogen therapy (EPT)
Trial: 17395393
Drug: CO2 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 inhalation test (exam group)
Trial: 17395393
Drug: CO2 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 inhalation test (non-exam group)
Trial: 17395393
Drug: CO2 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 inhalation test (both groups)
Trial: 7973660
Drug: Cholinergic antagonist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic antagonist, tropicamide, placed in the eyes of patients with Alzheimer's disease
Trial: 2637679
Drug: Morphine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administered via buccal route (controlled release formulation)
Trial: 2637679
Drug: Morphine-3-glucuronide and
RxNorm normalized name: MENTHOL GLUCURONIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-3-glucuronide and morphine-6-glucuronide
Trial: 29910016
Drug: In-session commitment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-session commitment statements (strength, frequency, and slope of strength) made in two therapy sessions
Trial: 29910016
Drug: Low pre-treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pre-treatment commitment to abstain and increasing commitment strength across a session
Trial: 26046730
Drug: Intracoronary BMMC
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary BMMC injection
Trial: 26046730
Drug: G‐CSF mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF mobilization (10 μg/kg/day subcutaneously for 5 days)
Trial: 26046730
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BMMC injection plus G‐CSF
Trial: 23239554
Drug: Cholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitor treatment for 6 months
Trial: 21198228
Drug: CBT4CBT (computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4CBT (computer-based cognitive-behavioral therapy)
Trial: 16556794
Drug: Oral proton
RxNorm normalized name: Protonix Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral proton pump inhibitor (pantoprazole 20 mg)
Trial: 12967069
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic agent
Trial: 12967069
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical anesthetic and pressure anesthesia
Trial: 12967069
Drug: No site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No site preparation (non-placebo control)
Trial: 10741595
Drug: Rapid induction
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid induction analgesia (RIA) conducted twice on 15 patients
Trial: 8543503
Drug: Meropenem monotherapy
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem monotherapy
Trial: 8723449
Drug: Ceftazidime plus
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime plus amikacin combination therapy
Trial: 23044498
Drug: 6% hydroxyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyl ethyl starch (HES) solution (Voluven)
Trial: 20819983
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication plus psychosocial intervention
Trial: 12474761
Drug: Medications for
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications for osteoporosis treatment
Trial: 1724102
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) infusion of 10 or 20 ng/kg/min
Trial: 1724102
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin substitution
Trial: 1724102
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prostacyclin and aprotinin
Trial: 6991541
Drug: Oral zomepirac
RxNorm normalized name: zomepirac
DrugBank: Zomepirac (DB04828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zomepirac 100 mg
Trial: 6991541
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine 16 mg
Trial: 6991541
Drug: Oral zomepirac
RxNorm normalized name: zomepirac
DrugBank: Zomepirac (DB04828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zomepirac
Trial: 26132512
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) application (AIGaAs diode, 810 nm, 100 mW, 2J/cm(2), 15 seconds per point)
Trial: 21289587
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 15 mg/kg body weight intravenously before incision
Trial: 11282177
Drug: Aerosolized rhDNase
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized rhDNase (2.5 mg daily) for 3 months
Trial: 9467148
Drug: Immediate diagnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate diagnosis and treatment
Trial: 25119609
Drug: IIV3-HD (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV3-HD (60 μg of hemagglutinin per strain)
Trial: 25119609
Drug: IIV3-SD (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV3-SD (15 μg of hemagglutinin per strain)
Trial: 19032175
Drug: Clamping method
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clamping method with BrAC-guided adjustments to maintain stable BrAC levels of 0.6 g l(‐1)
Trial: 19032175
Drug: Two-step prekinetic
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step prekinetic procedure with a target BrAC of 0.65 g l(‐1)
Trial: 12765659
Drug: Homemade liquid
RxNorm normalized name: Welmedix Homecare Pro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homemade liquid supplement
Trial: 10589806
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus subgingival application of metronidazole 25% dental gel (Elyzol) 5x during 10 days
Trial: 1755555
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (IN) 0.15 mg.kg‐1
Trial: 1755555
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam (IM) 0.15 mg.kg‐1
Trial: 31818232
Drug: Curcumin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (250 mg/day)
Trial: 31818232
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg/day)
Trial: 28560655
Drug: BioResponse DIM®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioResponse DIM® (BR-DIM) at 150 mg twice daily
Trial: 9679572
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with oral fluorouracil
Trial: 8023998
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine vasopressin (AVP) infusion (plasma AVP 16-20 pg/ml)
Trial: 2920304
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg, three times daily
Trial: 2920304
Drug: Disopyramide 200
RxNorm normalized name: disopyramide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide 200 mg single dose, three days after propranolol discontinuation
Trial: 2920304
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propranolol and disopyramide
Trial: 1093108
Drug: Methylphenidate (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (dosage range: 0.2 to 1.9 mg/kg)
Trial: 16339502
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) (0.625 mg/d)
Trial: 16339502
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus medroxyprogesterone acetate (MPA) (2.5 mg/d)
Trial: 6876944
Drug: Nicergoline (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (30 mg)
Trial: 6876944
Drug: Nicergoline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (15 mg) and Propranolol (20 mg)
Trial: 30935515
Drug: 2000 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg/day dried ginger powder for 12 weeks
Trial: 27179731
Drug: Newer generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer generation permanent polymer-coated drug-eluting stents (DES)
Trial: 25199531
Drug: Nine-month regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine-month regimen including clofazimine and high-dose moxifloxacin (can be extended to 11 months if needed)
Trial: 22897540
Drug: Young Parenthood
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Young Parenthood Program (YPP), a 10-week counseling program administered during pregnancy
Trial: 17980021
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A practices (didactic training and course materials in oral health screening, referral, counseling, and application of fluoride varnish)
Trial: 17980021
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B practices (same as Group A + weekly conference calls providing advice and support)
Trial: 15817595
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg taken daily for 5 years